Patent US5096916A successfully refreshed from Google Patents.
US5096916A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Treatment of chronic obstructive pulmonary disease (copd) by inhalation of an imidazoline
Assignee: Aegis Technology Inc
•
Filing: 1990-05-07
•
Granted: 1992-03-17
•
Expires: 2010-05-07
Abstract
Abstract A method of using an imidazoline compound, which is a vasodilator and an alpha-adrenergic blocking agent, for the treatment of symptoms of chronic obstructive pulmonary diseases (COPD), including cystic fibrosis, chronic bronchitis and emphysema, or COPD where it is associated with asthma, comprises administering the imidazoline to a patient by inhalation. Preferably, the imidazoline compound employed is tolazoline. The presentation of an imidazoline compound in a device for the administration of an aerosol is disclosed.
Inventors
- 👤 Alvaro H. Skupin
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 06:38
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0012; A61K9/007; A61K9/0073; A61K9/0075; A61K31/00; A61K31/33; A61K31/395; A61K31/41; A61K31/415; A61K9/008; A61P; A61P11/00
Claims Analysis
Total Claims: 10
Claim 1
Independent Claim
48 words
A method of treating chronic obstructive pulmonary disease, or COPD where it is associated with asthma, wherein the method comprises administering to a patient by inhalation an alpha-adrenergic blocking agent of the formula ##STR8## in an amount sufficient to alleviate the respiratory distress of chronic obstructive pulmonary disease.
Claim 2
Independent Claim
48 words
A method of treating chronic obstructive pulmonary disease, or COPD where it is associated with asthma, wherein the method comprises administering to a patient by inhalation an alpha-adrenergic blocking agent of the formula ##STR8## in an amount sufficient to alleviate the respiratory distress of chronic obstructive pulmonary disease.
Claim 3
Dependent Claim
11 words
The method of claim 1, wherein the patient is a human.
Claim 4
Dependent Claim
15 words
The method of claim 1, wherein the patient is a mammal other than a human.
Claim 5
Dependent Claim
17 words
The method of claim 1, wherein tolazoline is administered to the patient in a pharmaceutically acceptable carrier.
Claim 6
Dependent Claim
15 words
The method of claim 1, wherein tolazoline is administered to a patient in a propellant.
Claim 7
Dependent Claim
19 words
The method of claim 1, wherein about 4 to about 100 mg of tolazoline is administered to the patient.
Claim 8
Dependent Claim
18 words
The method of claim 6, wherein about 4 to 12 mg of tolazoline is administered to the patient.
Claim 9
Dependent Claim
27 words
The method of claim 1, wherein the chronic obstructive pulmonary disease to be treated, is selected from the group consisting of cystic fibrosis, chronic bronchitis, and emphysema.
Claim 10
Dependent Claim
16 words
The method of claim 8, wherein said chronic obstructive pulmonary disease is also associated with asthma.
References Cited (Backward Citations)
US2161938A
Cited
US4255439A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1995-03-17 | 1995-09-16 | 1996-03-17 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1999-03-17 | 1999-09-16 | 2000-03-17 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2003-03-17 | 2003-09-16 | 2004-03-17 | $7700.00 | Window Closed / Lapsed |